Glucocorticoid and Mineralocorticoid Dosing Regimens

General Principles

The American College of Rheumatology recommends that glucocorticoid and mineralocorticoid therapy should be tailored to the specific condition being treated, with careful consideration of dosing regimens that minimize adverse effects while maximizing therapeutic benefit 1
Initial dose, dose reduction, and long-term dosing depend on the underlying rheumatic disease, disease activity, risk factors, and individual patient responsiveness 1, 2
Daily dosing is conditionally recommended over alternate-day schedules for conditions like giant cell arteritis (GCA), as it provides higher remission rates 3
For prolonged treatment, glucocorticoid dosage should be kept to a minimum, and tapering should be attempted when remission or low disease activity is achieved 2, 4
Timing may be important with respect to circadian rhythm of both disease and natural glucocorticoid secretion; morning administration is generally preferred 2

Condition-Specific Regimens

For newly diagnosed GCA: High-dose oral glucocorticoids initially, followed by tapering 3
For GCA with threatened vision loss: IV pulse glucocorticoids conditionally recommended 3
For GCA with active extracranial large vessel involvement: Oral glucocorticoids combined with non-glucocorticoid immunosuppressive agents (e.g., tocilizumab) 3
For primary adrenal insufficiency: Hydrocortisone (HC): 15-25 mg/day in divided doses 4, 5
For primary adrenal insufficiency: Cortisone acetate (CA): 25-37.5 mg/day in divided doses 5
For primary adrenal insufficiency: Prednisolone: 4-5 mg/day (alternative option) 5

Mineralocorticoid Therapy

Standard mineralocorticoid replacement (fludrocortisone): 0.05-0.2 mg (50-200 μg) once daily in the morning for primary adrenal insufficiency 5
Higher doses (up to 500 μg daily) may be needed in children, younger adults, or during the last trimester of pregnancy when high levels of progesterone counteract mineralocorticoids 5

Monitoring and Risk Management

Before starting glucocorticoid therapy, comorbidities and risk factors for adverse effects should be evaluated and treated 2
For patients on prednisone >7.5 mg daily for more than 3 months, calcium and vitamin D supplementation should be prescribed 2, 6
Antiresorptive therapy with bisphosphonates should be considered based on risk factors, including bone mineral density measurement 2
Patients treated with glucocorticoids and concomitant NSAIDs should receive appropriate gastroprotective medication 2
Regular monitoring should include body weight, blood pressure, peripheral edema, cardiac insufficiency, serum lipids, blood/urine glucose, and ocular pressure 2, 7

Special Considerations

All patients on glucocorticoid therapy for longer than 1 month who undergo surgery need perioperative management with adequate glucocorticoid replacement 2, 5
During acute illness, surgery, or trauma, glucocorticoid doses should be increased 5
Glucocorticoids during pregnancy have no additional risk for mother and child 2
Fludrocortisone dose may need to be increased in the third trimester of pregnancy due to progesterone's antimineralocorticoid effects 5
Children receiving glucocorticoids should be checked regularly for linear growth 2
Growth hormone replacement should be considered in case of growth impairment 2
Certain medications can affect hydrocortisone metabolism, requiring dose adjustments 5
Patients should carry a steroid card or wear a medical alert bracelet to inform healthcare providers of chronic glucocorticoid use 4, 5

Glucocorticoid and Mineralocorticoid Therapy

Introduction to Glucocorticoid Dosing

The European League Against Rheumatism recommends low-dose glucocorticoid therapy (≤7.5 mg/day prednisone equivalent) for patients with rheumatoid arthritis, with a strength of evidence rated as high 8, 9
The American College of Rheumatology suggests medium-dose glucocorticoid therapy (>7.5 mg/day to ≤30 mg/day prednisone equivalent) for patients with rheumatoid arthritis, with a strength of evidence rated as moderate 8, 9
High-dose glucocorticoid therapy (>30 mg/day to ≤100 mg/day prednisone equivalent) is recommended for patients with severe rheumatoid arthritis, with a strength of evidence rated as low 9

Glucocorticoid Dosing Regimens by Condition

For rheumatoid arthritis, the initial dose is 15-20 mg/day, with a rapid reduction to 15 mg by 12 weeks, and a long-term goal of ≤5 mg/day, according to the European League Against Rheumatism, with a strength of evidence rated as high 10, 11
For ANCA-associated vasculitis, the remission induction dose is 1 mg/kg/day, with a maintenance dose of 15 mg by 12 weeks, and a reduced-dose regimen of 50% reduction in the second week, according to the British Medical Journal, with a strength of evidence rated as moderate 10, 11, 12
For polymyalgia rheumatica, the initial dose is 12.5-25 mg/day, with a taper of 1 mg every 4 weeks once remission is achieved, and avoidance of high doses (>30 mg/day), according to the European League Against Rheumatism, with a strength of evidence rated as moderate 13
For Duchenne muscular dystrophy, the daily dose is 0.75 mg/kg/day, with alternative regimens of 0.75-1.25 mg/kg every other day or 5 mg/kg on weekends only, according to The Lancet Neurology, with a strength of evidence rated as low 14

Mineralocorticoid Dosing and Uses

For primary adrenal insufficiency, the standard dose is 0.05-0.2 mg (50-200 μg) once daily, with higher doses (up to 500 μg daily) needed in children, younger adults, or during pregnancy, according to the Endocrine Society, with a strength of evidence rated as moderate 15, 16

Side Effects and Risk Management

Glucocorticoid therapy is associated with an increased risk of osteoporosis (1-3 events per 100 patient-years), diabetes (0-13 events per 100 patient-years), and hypertension (0-63 events per 100 patient-years), according to the European League Against Rheumatism, with a strength of evidence rated as high 8
Mineralocorticoid therapy is associated with an increased risk of hypertension, peripheral edema, and hypokalemia, according to the Endocrine Society, with a strength of evidence rated as moderate 15

Special Considerations

Stress dosing is recommended for patients with adrenal insufficiency, with an increase in glucocorticoid dose during acute illness, surgery, or trauma, according to the Endocrine Society, with a strength of evidence rated as high 8, 16
Fludrocortisone dose may need to be increased (up to 500 μg daily) in the third trimester of pregnancy due to progesterone's antimineralocorticoid effects, according to the Endocrine Society, with a strength of evidence rated as moderate 15, 16

Glucocorticoid Therapy

Introduction to Glucocorticoid Tolerance

The European League Against Rheumatism recommends that for most patients, prednisolone and low-dose prednisone (≤7.5 mg/day) are the best-tolerated glucocorticoids, with deflazacort as an alternative that may have fewer side effects in specific populations 17, 18

Choosing the Right Glucocorticoid

The American College of Rheumatology suggests that prednisolone and prednisone are standard glucocorticoids for long-term treatment, with a well-established side effect profile when used at low doses (≤7.5 mg/day equivalent prednisone) 18
The European League Against Rheumatism recommends that deflazacort may be better tolerated in certain situations, such as in patients with problematic weight gain or behavioral disturbances under prednisone, although it is less effective than daily prednisone regimens 17

Dosage Strategies to Optimize Tolerance

The American College of Rheumatology recommends maintaining the glucocorticoid dose at the minimum necessary and attempting gradual reduction in case of remission or low disease activity 18
The European League Against Rheumatism suggests that for patients with rheumatoid arthritis, the goal is ≤5 mg/day long-term after an initial induction phase of 15-20 mg/day with rapid reduction to 15 mg at 12 weeks 18
The American Academy of Neurology recommends that the minimum effective dose showing benefit (although not maximal) is 0.3 mg/kg/day for prednisone in certain conditions such as Duchenne muscular dystrophy 17

Alternative Dosing Schemes in Case of Intolerance

The European League Against Rheumatism recommends considering alternative dosing schemes, such as every-other-day regimens (0.75-1.25 mg/kg of prednisone every 2 days), weekend high-dose regimens (5 mg/kg of prednisone every Friday and Saturday), or intermittent regimens (0.75 mg/kg of prednisone for 10 days alternating with 10-20 days without medication) in case of intolerance to daily regimens 17

Management of Side Effects to Improve Tolerance

The American College of Rheumatology recommends evaluating and treating hypertension, diabetes, gastroduodenal ulcer, recent fractures, cataract or glaucoma, infections (chronic), dyslipidemia, and concomitant medication with NSAIDs before starting glucocorticoid therapy 18
The European League Against Rheumatism suggests regularly monitoring weight, blood pressure, peripheral edema, heart failure, serum lipids, blood/urine glucose, and eye pressure according to individual patient risk, dose, and duration of glucocorticoid therapy 18
The American College of Rheumatology recommends systematic prophylaxis, including calcium (800-1000 mg/day) and vitamin D (400-800 units/day) supplementation for prednisone >7.5 mg/day for more than 3 months, and antiresorptive therapy with bisphosphonates based on risk factors, including bone mineral density measurement 18

Special Considerations According to Clinical Context

The European League Against Rheumatism recommends that morning administration is generally preferred to respect the circadian rhythm of natural glucocorticoid secretion 18
The American Academy of Neurology suggests that for children with transient behavioral disturbances (hyperactivity, emotional lability) a few hours after intake, afternoon administration after school may be preferred 17
The American College of Rheumatology recommends continuing the current daily dose rather than administering supraphysiological "stress" doses for patients receiving ≤16 mg/day equivalent prednisone for a rheumatic condition undergoing elective surgery 19
The European League Against Rheumatism suggests that for patients on glucocorticoids for more than 1 month undergoing surgery, perioperative management with adequate glucocorticoid replacement is necessary to overcome potential adrenal insufficiency 18

Common Pitfalls to Avoid

The American College of Rheumatology recommends not using higher doses than necessary, as higher doses of glucocorticoids are generally not more effective and increase the risk of side effects 17
The European League Against Rheumatism suggests not stopping abruptly after more than 3-4 weeks of use, as gradual tapering is necessary to prevent adrenal insufficiency due to suppression of the hypothalamic-pituitary-adrenal axis 17
The American College of Rheumatology recommends not neglecting bone prophylaxis, as glucocorticoid-induced osteoporosis is a major risk requiring systematic prevention 18